Rakesh K Jain

This inventor holds 34 USPTO granted patents and 12 published patent applications and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: The General Hospital Corporation, Ardelyx, Inc., Novabay Pharmaceuticals, Inc.. Active years: 1995-2025.

USPTO Granted Patents = 34 (Patent Applications = 12)

% Patents Active = 76.5

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 200(Granted Patents)

Location History:

Gilroy, CA (US) (1995 - 1997)
Boston, MA (US) (1995 - 2004)
Danville, CA (US) (2014 - 2019)
Freemont, CA (US) (2020)
Wellesley, MA (US) (2015 - 2022)
Fremont, CA (US) (2004 - 2024)

Company Filing History:

14 out of 3,070

The General Hospital Corporation

Novabay Pharmaceuticals, Inc.

Massachusetts Institute of Technology

patents

6. 3 out of 23

Vicuron Pharmaceuticals Inc.

Xtuit Pharmaceuticals, Inc.

patent

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

Areas of Expertise:

Hormone Receptor Modulators

TGR5 Agonists

FXR Activators

Cancer Stem Cells

Anti-Angiogenic Therapy

Nanoparticle Drug Delivery

Antimicrobials

Tumor Targeting

Microcapsules

Pharmaceutical Formulations

Solid Tumors

Drug Delivery Systems

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209088 - Hormone receptor modulators for treating metabolic conditions and disorders (2025-01-28),

2. 12084472 - Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists (2024-09-10),

3. 11718619 - Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators (2023-08-08),

4. 11433136 - Polyacetal polymers, conjugates, particles and uses thereof (2022-09-06),

5. 11427543 - Compounds for targeting cancer stem cells (2022-08-30),

6. 11351144 - Compounds for inhibiting secretory leukocyte protease inhibitor (SLPI) (2022-06-07),

7. 11279765 - Compositions and methods to improve anti-angiogenic therapy and immunotherapy (2022-03-22),

8. 11259714 - System and method for measuring solid stress in tissues (2022-03-01),

9. 11091482 - Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators (2021-08-17),

10. 10968246 - Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists (2021-04-06),

11. 10793568 - Hormone receptor modulators for treating metabolic conditions and disorders (2020-10-06),

12. 10689459 - Treatment of breast cancer brain metastases (2020-06-23),

13. 10392413 - Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists (2019-08-27),

14. 9919059 - Multistage nanoparticle drug delivery system for the treatment of solid tumors (2018-03-20),

15. 9248117 - Substituted N,N-dihaloamines as antimicrobials (2016-02-02),

Title: The Innovative Mind of Rakesh K Jain

Introduction: Rakesh K Jain, a distinguished inventor based in Wellesley, MA (US), is renowned for his groundbreaking contributions to the field of medical innovations.

Latest Patents: Rakesh K Jain holds several patents related to advanced drug delivery systems and targeted cancer therapies, revolutionizing the way medical treatments are administered.

Career Highlights: With a career spanning several decades, Rakesh K Jain has held prominent positions in leading research institutions and universities, where he has spearheaded numerous projects that have significantly impacted the medical industry.

Collaborations: Throughout his career, Rakesh K Jain has collaborated with top pharmaceutical companies, renowned scientists, and medical professionals to further his research and bring his innovative ideas to life.

Conclusion: Rakesh K Jain's relentless pursuit of innovation and his dedication to improving medical treatments have solidified his position as a pioneering inventor in the field of healthcare.